Mutations of telomerase reverse transcriptase promoter (TERTp) were subsequently found to frequently occur in gliomas (Lee et al., (2017)) and to be associated with a better outcome in the IDH mutation subgroup but a poorer outcome in the IDH wild‐type subgroup (Pekmezci et al., 2017). This evidence concerns the gene IDH2 and glioma.